The Journal of Infectious Diseases · 2020 · 82 citations · 20 references
Veterinary MedicineImmunologyInfectious DiseasesImmunology Of Infectious DiseasesImmunopathologyVirologyHumoral ImmunityImmunopathology Of Infectious DiseasesRespiratory Infectious DiseasesViral InfectionsViral Vector VaccinesComparative Disease SeverityDisease Severity EstimationHumoral Immune Responses To VectorsLentiviral VectorsSars-cov-2 InfectionSevere Acute Respiratory Syndrome
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a pandemic with tens of millions of cases and hundreds of thousands of deaths. The infection causes coronavirus disease 2019 (COVID-19), a disease of the respiratory system of divergent severity. In the current study, humoral immune responses were characterized in a cohort of 143 patients with COVID-19 from the University Hospital Frankfurt am Main, Germany. METHODS: SARS-CoV-2-specific-antibodies were detected by enzyme-linked immunosorbent assay (ELISA). SARS-CoV-2 and human coronavirus NL63 neutralization activity was analyzed with pseudotyped lentiviral vectors. RESULTS: The severity of COVID-19 increased with age, and male patients encountered more serious symptoms than female patients. Disease severity was correlated with the amount of SARS-CoV-2-specific immunoglobulin (Ig) G and IgA and the neutralization activity of the antibodies. The amount of SARS-CoV-2-specific IgG antibodies decreased with time after polymerase chain reaction conformation of the infection, and antibodies directed against the nucleoprotein waned faster than spike protein-directed antibodies. In contrast, for the common flu coronavirus NL63, COVID-19 disease severity seemed to be correlated with low NL63-neutralizing activities, suggesting the possibility of cross-reactive protection. CONCLUSION: The results describe the humoral immune responses against SARS-CoV-2 and might aid the identification of correlates of protection needed for vaccine development.
20
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls, Young‐Jun Park, M. Alejandra Tortorici et al. · Cell · 2020 · 9.1K citations · Full text
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Nina Le Bert, Anthony T. Tan, Kamini Kunasegaran et al. · Nature · 2020 · 2.2K citations · Full text
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Davide F. Robbiani, Christian Gaebler, Frauke Muecksch et al. · Nature · 2020 · 2.1K citations · Full text